RE:RE:RE:RE:Walls gonna break soon just to put it into perspective.
If a gentleman like
Noel Atkinson is making comments like this We believe StageZero’s proprietary Aristotle platform is positioned to become a leading liquid biopsy solution,” he argued. “It can identify ten different types of cancer from a single blood test and catch cancer at even the earliest stages. Unlike drugs, most diagnostic tests do not need regulatory approval before commercial launch, and we expect Aristotle revenues to begin in the U.S., Canada, and Europe by Q1/21. Aristotle could be the first commercially-available multi-cancer liquid biopsy product, and we expect rapid revenue growth during our forecast period ending 2022. The peer group of liquid biopsy companies trades at a very substantial price/sales multiple, so if Aristotle can achieve market acceptance, we expect StageZero’s share price to rise significantly from current levels.” I sleep well at night knowing the money is going to be flowing very shortly.
SAGDollar wrote: I'm calm just like Clarus https://www.cantechletter.com/2020/08/stagezero-life-sciences-has-a-massive-upside-clarus-securities-says/